SynopsisIndoprofen(CAS 31842-01-0) is a non-steroidal drug, which can show a range of pharmacological properties such as analgesic and anti-inflammatory activities. The global Indoprofen market was valued at US$ million in 2023 and is anticipated to reach US$ mi.....
SynopsisPeficitinib(CAS 944118-01-8) is a novel potent JAK inhibitor, which demonstrated potent efficacy in adjuvant-induced arthritis model in rats. The global Peficitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030,.....
SynopsisBaricitinib (CAS 1187594-09-7) is an orally bioavailable inhibitor of Janus kinases 1 and 2, with potential anti-inflammatory, immunomodulating and antineoplastic activities. The global Baricitinib market was valued at US$ million in 2023 and is anticipa.....
SynopsisValrubicin (CAS 56124-62-0) is a semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. The global Valrubicin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % d.....
SynopsisPreladenant (CAS 377727-87-2) is a potent and selective antagonist at the adenosine A2A receptor. The global Preladenant market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast .....
SynopsisMonomethyl Fumarate (CAS 2756-87-8), the active metabolite of the psoriasis drug Fumaderm, is a potent GPR109A agonist. The global Monomethyl Fumarate market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a .....
SynopsisAcebilustat (CAS 943764-99-6), also known as ZK322, is a novel, oral, potent and selective leukotriene A4 hydrolase inhibitor that is a promising new once-daily oral antiinflammatory drug in development for treatment of cystic fibrosis (CF) and other diseases......
SynopsisDithranol (CAS 1143-38-0) is a hepsin activity inhibitor used for treatment of psoriasis. Dithranol exerts a direct effect on keratinocytes and leukocytes. The global Dithranol market was valued at US$ million in 2023 and is anticipated to reach US$ mill.....
SynopsisZalcitabine (CAS 7481-89-2) is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI). The global Zalcitabine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast pe.....
SynopsisBiochanin A (CAS 491-80-5) is a nitric oxide synthase inhibitor and apoptosis inducer. The global Biochanin A market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024.....
